ATE233814T1 - Humaner neutralisierender monoklonaler antikörper gegen den die immunschwäche beim menschen hervorringenden virus - Google Patents
Humaner neutralisierender monoklonaler antikörper gegen den die immunschwäche beim menschen hervorringenden virusInfo
- Publication number
- ATE233814T1 ATE233814T1 AT93923749T AT93923749T ATE233814T1 AT E233814 T1 ATE233814 T1 AT E233814T1 AT 93923749 T AT93923749 T AT 93923749T AT 93923749 T AT93923749 T AT 93923749T AT E233814 T1 ATE233814 T1 AT E233814T1
- Authority
- AT
- Austria
- Prior art keywords
- human
- virus
- monoclonal antibody
- antibody against
- immune deficiency
- Prior art date
Links
- 241000700605 Viruses Species 0.000 title 1
- 230000007812 deficiency Effects 0.000 title 1
- 230000003472 neutralizing effect Effects 0.000 title 1
- 241000725303 Human immunodeficiency virus Species 0.000 abstract 2
- 238000002405 diagnostic procedure Methods 0.000 abstract 1
- 230000001024 immunotherapeutic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1036—Retroviridae, e.g. leukemia viruses
- C07K16/1045—Lentiviridae, e.g. HIV, FIV, SIV
- C07K16/1063—Lentiviridae, e.g. HIV, FIV, SIV env, e.g. gp41, gp110/120, gp160, V3, PND, CD4 binding site
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
- A61K49/10—Organic compounds
- A61K49/14—Peptides, e.g. proteins
- A61K49/16—Antibodies; Immunoglobulins; Fragments thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/035—Fusion polypeptide containing a localisation/targetting motif containing a signal for targeting to the external surface of a cell, e.g. to the outer membrane of Gram negative bacteria, GPI- anchored eukaryote proteins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Virology (AREA)
- Veterinary Medicine (AREA)
- Genetics & Genomics (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Communicable Diseases (AREA)
- AIDS & HIV (AREA)
- Hematology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Physics & Mathematics (AREA)
- Optics & Photonics (AREA)
- Radiology & Medical Imaging (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US95414892A | 1992-09-30 | 1992-09-30 | |
PCT/US1993/009328 WO1994007922A1 (en) | 1992-09-30 | 1993-09-30 | Human neutralizing monoclonal antibodies to human immunodeficiency virus |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE233814T1 true ATE233814T1 (de) | 2003-03-15 |
Family
ID=25495000
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT93923749T ATE233814T1 (de) | 1992-09-30 | 1993-09-30 | Humaner neutralisierender monoklonaler antikörper gegen den die immunschwäche beim menschen hervorringenden virus |
Country Status (10)
Country | Link |
---|---|
EP (1) | EP0675904B1 (de) |
JP (1) | JPH08502260A (de) |
AT (1) | ATE233814T1 (de) |
AU (1) | AU681360B2 (de) |
CA (1) | CA2145757A1 (de) |
DE (1) | DE69332744T2 (de) |
ES (1) | ES2194015T3 (de) |
FI (1) | FI951488A (de) |
NO (1) | NO951212L (de) |
WO (1) | WO1994007922A1 (de) |
Families Citing this family (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1995020401A1 (en) | 1994-01-31 | 1995-08-03 | Trustees Of Boston University | Polyclonal antibody libraries |
US6987096B1 (en) | 1995-04-27 | 2006-01-17 | The United States Of America As Represented By The Department Of Health And Human Services | Antiviral proteins and peptides, DNA coding sequences therefor, and uses thereof |
US6780847B2 (en) | 1995-04-27 | 2004-08-24 | The United States Of America As Represented By The Department Of Health And Human Services | Glycosylation-resistant cyanovirins and related conjugates, compositions, nucleic acids, vectors, host cells, methods of production and methods of using nonglycosylated cyanovirins |
US6428790B1 (en) | 1995-04-27 | 2002-08-06 | The United States Of America As Represented By The Secretary Department Of Health And Human Services | Cyanovirin conjugates and matrix-anchored cyanovirin and related compositions and methods of use |
US5843882A (en) | 1995-04-27 | 1998-12-01 | The United States Of America As Represented By The Department Of Health And Human Services | Antiviral proteins and peptides |
US6193982B1 (en) | 1995-04-27 | 2001-02-27 | The United States Of America As Represented By The Department Of Health & Human Services | Anti-cyanovirin antibody with an internal image of gp120, a method of use thereof, and a method of using a cyanovirin to induce an immune response to gp120 |
US7048935B2 (en) | 1995-04-27 | 2006-05-23 | The United States Of America As Represented By The Department Of Health And Human Services | Cyanovirin conjugates and matrix-anchored cyanovirin and related compositions and methods of use |
US6255455B1 (en) | 1996-10-11 | 2001-07-03 | The Trustees Of The University Of Pennsylvania | Rh(D)-binding proteins and magnetically activated cell sorting method for production thereof |
DE19809785C2 (de) * | 1998-03-08 | 2000-02-10 | Wolfgang Bergter | Radioimmunpharmakon zur Behandlung der HIV-1-Infektion |
JP2002519334A (ja) * | 1998-06-29 | 2002-07-02 | ベルクター,ヴォルフガンク | αエミッタとβエミッタとを主成分とする抗ウイルスおよび抗レトロウイルス放射免疫薬剤 |
EP1141314A2 (de) | 1998-12-31 | 2001-10-10 | Chiron Corporation | Für antigene polypeptide des hiv type c kodierende polynukleotide, entsprechende polypeptide und verwendungen davon |
GB9908533D0 (en) | 1999-04-14 | 1999-06-09 | Novartis Ag | Organic compounds |
DK1276855T3 (da) | 2000-04-17 | 2012-11-26 | Dyax Corp | Fremgangsmåde til konstruktion af visningsbiblioteker over genetiske pakker for medlemmer af en diversificeret peptidfamilie |
US8288322B2 (en) * | 2000-04-17 | 2012-10-16 | Dyax Corp. | Methods of constructing libraries comprising displayed and/or expressed members of a diverse family of peptides, polypeptides or proteins and the novel libraries |
EP1360288B1 (de) | 2000-12-18 | 2011-02-16 | Dyax Corp. | Gerichtete bibliotheken die genetisch verpackt sind |
JP4307841B2 (ja) | 2001-03-22 | 2009-08-05 | アメリカ合衆国 | グリコシル化抵抗性シアノビリン及び関連コンジュゲート、組成物、核酸、ベクター、宿主細胞、非グリコシル化シアノビリンの製造方法及び使用方法 |
AU2002320314A1 (en) | 2001-07-05 | 2003-01-21 | Chiron, Corporation | Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof |
EP1450857B1 (de) | 2001-10-16 | 2010-09-15 | The Government of the United States of America, represented by The Secretary, Department of Health and Human Services | Neutralisierende antikörper gegen hiv mit breiter kreuzreaktion, die mit hilfe von env-cd4-co-rezeptorkomplexen selektiert werden |
CA2484930A1 (en) | 2002-05-06 | 2003-11-13 | The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Identification of novel broadly cross-reactive neutralizing human monoclonal antibodies using sequential antigen panning of phage display libraries |
EP1504034B1 (de) | 2002-05-06 | 2012-12-12 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | Identifikation neuer breitkreuzreaktiver hiv-1-neutralisierender humaner monoklonaler antikörper |
US20040067532A1 (en) | 2002-08-12 | 2004-04-08 | Genetastix Corporation | High throughput generation and affinity maturation of humanized antibody |
WO2006050219A2 (en) * | 2004-10-29 | 2006-05-11 | Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Broadly cross-reactive hiv-1 neutralizing human monoclonal antibodies |
US8877688B2 (en) | 2007-09-14 | 2014-11-04 | Adimab, Llc | Rationally designed, synthetic antibody libraries and uses therefor |
CA2697193C (en) | 2007-09-14 | 2017-06-06 | Adimab, Inc. | Rationally designed, synthetic antibody libraries and uses therefor |
WO2009114815A1 (en) | 2008-03-13 | 2009-09-17 | Dyax Corp | Libraries of genetic packages comprising novel hc cdr3 designs |
EP2281078B1 (de) | 2008-04-24 | 2014-10-22 | Dyax Corporation | Bibliotheken von genetischen packungen, umfassend neue hc-cdr1, -cdr2, und -cdr3, und neue lc-cdr1-, -cdr2- und -cdr3-designs |
AU2011279073B2 (en) | 2010-07-16 | 2016-06-09 | Adimab, Llc | Antibody libraries |
EP2492279A1 (de) | 2011-02-25 | 2012-08-29 | Laboratorios Del. Dr. Esteve, S.A. | Schnelles immunogenes Auswahlverfahren mittels Lentivirenanzeige |
EP2698377A1 (de) | 2012-08-17 | 2014-02-19 | Laboratorios Del. Dr. Esteve, S.A. | Verbessertes schnelles Immunogene Auswahlverfahren für HIV gp120 Varianten |
KR20230019227A (ko) * | 2017-11-17 | 2023-02-07 | 그리폴스 다이어그노스틱 솔루션즈 인크. | 신규한 포유동물 발현 인간 면역결핍 바이러스 외피 단백질 항원 |
IL294218A (en) | 2019-12-27 | 2022-08-01 | Chiome Bioscience Inc | Antibody against cdcp1 |
CN116963779A (zh) | 2020-09-02 | 2023-10-27 | 国立大学法人东京大学 | 癌症免疫微环境的调节物质及其预防、诊断或治疗 |
CN112521492B (zh) * | 2020-12-18 | 2022-05-20 | 杭州贤至生物科技有限公司 | 乙肝表面抗原单克隆抗体的制备 |
-
1993
- 1993-09-30 AU AU53501/94A patent/AU681360B2/en not_active Ceased
- 1993-09-30 CA CA002145757A patent/CA2145757A1/en not_active Abandoned
- 1993-09-30 DE DE69332744T patent/DE69332744T2/de not_active Expired - Fee Related
- 1993-09-30 AT AT93923749T patent/ATE233814T1/de not_active IP Right Cessation
- 1993-09-30 EP EP93923749A patent/EP0675904B1/de not_active Expired - Lifetime
- 1993-09-30 WO PCT/US1993/009328 patent/WO1994007922A1/en active IP Right Grant
- 1993-09-30 JP JP6509318A patent/JPH08502260A/ja not_active Ceased
- 1993-09-30 ES ES93923749T patent/ES2194015T3/es not_active Expired - Lifetime
-
1995
- 1995-03-29 FI FI951488A patent/FI951488A/fi not_active Application Discontinuation
- 1995-03-29 NO NO951212A patent/NO951212L/no unknown
Also Published As
Publication number | Publication date |
---|---|
AU681360B2 (en) | 1997-08-28 |
NO951212D0 (no) | 1995-03-29 |
DE69332744D1 (de) | 2003-04-10 |
ES2194015T3 (es) | 2003-11-16 |
DE69332744T2 (de) | 2004-01-15 |
FI951488A (fi) | 1995-05-23 |
FI951488A0 (fi) | 1995-03-29 |
NO951212L (no) | 1995-05-29 |
EP0675904A1 (de) | 1995-10-11 |
CA2145757A1 (en) | 1994-04-14 |
EP0675904B1 (de) | 2003-03-05 |
JPH08502260A (ja) | 1996-03-12 |
EP0675904A4 (de) | 1996-08-21 |
WO1994007922A1 (en) | 1994-04-14 |
AU5350194A (en) | 1994-04-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE233814T1 (de) | Humaner neutralisierender monoklonaler antikörper gegen den die immunschwäche beim menschen hervorringenden virus | |
EP0724651A4 (de) | Synthetische humane neutralisierende monoklonale antikörper gegen den die immunschwäche auslösenden virus aus mensch | |
NO970221L (no) | Humane nöytraliserende monoklonale antistoffer mot humant immunsviktvirus | |
NO950881D0 (no) | Nöytraliserende monoklonale menneske-antistoffer mot andedretts-syncytial-virus | |
HK1044159A1 (zh) | 抗γ-干擾素的人化抗體 | |
HUP9802212A2 (hu) | Humán terápiában alkalmazható rekombináns anti-CD4-ellenanyagok | |
DE69429095D1 (de) | Humanisierte antikoerper | |
CO4480111A1 (es) | Anticuerpos monoclonales de mono especificos para humanos b7. y/o b7.2, formas primatizadas de los mismos, composicio- nes farmaceuticas que los contienen, y uso de los mismos co- mo inmunosupresantes | |
MXPA03002480A (es) | Inmunogeno que comprende ligando enlazado a proteinas de envoltura de vih. | |
TW200517121A (en) | Immunogen | |
WO2004009785A3 (en) | IgG Fc/HIV-gp120/C3d FUSION PROTEIN | |
SG48816A1 (en) | Gonococcal anti-idiotypic antibodies and methods and compositions using them | |
CA2106719A1 (en) | Reshaped monoclonal antibodies against an immunoglobulin isotype | |
MX9301858A (es) | Anticuerpos monoclonales neutralizantes de hiv-humano recombinante para prevencion y tratamiento de infeccion hiv. | |
SE9201281D0 (sv) | New human monoclonal antibodies, and a method for preparation thereof | |
WO1991010735A3 (fr) | Recepteur humain de la tsh. sequence codant pour ce recepteur | |
DK0585570T3 (da) | Granulocytbindende antistofkonstrukter, deres fremstilling og anvendelse | |
ATE208403T1 (de) | Antiidiotypische antikörper die eine immunantwort gegen den rezeptor für epidermalen wachstumsfaktor induzieren | |
AU4959193A (en) | High affinity, strongly neutralizing monoclonal antibodies against the CD-4 binding site of GP120 of human immunodeficiency virus | |
DE68925365D1 (de) | PEPTIDE, DIE EPITOPE AUF R-IFN-BETA REPRÄSENTIEREN, ANTIKöRPER DAGEGEN, UND IHRE ANWENDUNG | |
DE59207362D1 (de) | Monoklonale Antikörper gegen den Plasmin-Antiplasmin Komplex, Verfahren zu ihrer Herstellung sowie ihre Verwendung | |
DE69617255D1 (de) | Durch hla-b44 moleküle präsentierte tumor-abstossungsantigene und ihre verwendung | |
ATE108832T1 (de) | Verwendung von monoklonalen antikörpern gegen b2- mikroglobulin. | |
ES2051870T3 (es) | Anticuerpo monoclonal capaz de suprimir la proliferacion de linfocitos t. | |
ES2088820A1 (es) | Anticuerpos monoclonales antineumolisina. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |